Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years.

Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)

On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman device. The study positions Boston Scientific’s Watchman as a potential first-line alternative to medication therapy, which could drive an annual revenue rise of 250 basis points later in the decade.

This follows recent turbulence caused by investor concerns around cardiology performance in Q3. Over the past 12 months, however, Boston Scientific has demonstrated excellent execution, as shown by its 21.4% sales increase.

Through its MedSurg and Cardiovascular segments, Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and distributes medical devices for use across a wide range of interventional specialties worldwide. It is one of the Stocks That Will Double.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.